You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Two studies examined the emergence and spread of SARS-CoV-2 viral variants and lineages, and highlighted the need for genomic viral surveillance.
The agreement, which provides an unsecured five-year revolving credit facility, includes an option for Illumina to take out additional loans of up to $250 million.
The study uncovered virus-specific as well as shared host factors, including a lysosomal protein that SARS-CoV-2 requires to infect primary lung cells.
The test leverages immune repertoire sequencing technology to identify individuals who have had a recent or prior SARS-CoV-2 infection.
The company is studying hibernating animals to see if their genomes contain novel biological pathways that could be exploited to counteract complex human diseases.
R-Pharm, Illumina's strategic partner in Russia and the Commonwealth of Independent States (CIS), led the registration process with the Russian regulatory agency.
The Temple City, California-based firm delivered approximately 3.2 million billable tests in the quarter and recorded $295.0 million in revenues.
The firm will build liquid biopsy companion diagnostic tests that complement its tissue-based assays and are tailored for drugs developed by pharma partners.
Two studies identified common and rare regulatory variants in iPSC lines, including those with ties to disease or differentiation.
C2i said that the acquisition would help it commercialize its MRDetect cancer monitoring platform as a reimbursable laboratory-developed test.
The Wellcome Sanger Institute and the BC Centre for Disease Control Public Health Lab have been using viral sequencing to follow the spread of variants of concern.
Bio-Techne said Asuragen's headquarters in Austin, Texas includes a scalable 50,000-square-foot manufacturing facility and CLIA-certified laboratory.
At AGBT, UCSC's Karen Miga provided updates on the human pangenome reference project and the telomere-to-telomere consortium's genome assembly work.
The assay is being positioned as an alternative to next-generation sequencing-based approaches, which its creators view as ponderous and pricey.
The companies will partner on applications including oncology diagnostics, cell-free and circulating tumor DNA assays, and single-cell genomics.
The tools are part of Molecular Health's MH Guide platform, which analyzes sequencing data to identify and report on disease-related gene variants.
Pfizer is the first drugmaker to join the Strata PATH platform trial and will contribute drugs to advanced cancer patients in four study arms.
The new service, slated for launch in the second half of 2021, will allow Myriad to expand its cancer tumor profiling services.
The liquid biopsy method analyzes fragment ends within recurrently protected regions in cell-free DNA from a patient's urine sample.
SUGAR-seq, a single-cell method developed by researchers in Australia, is a first step towards analyzing differences in glycosylation in various cell types.
Nature News writes that viral genomic surveillance in the US faces systemic issues.
President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.
A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.
In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.